France Rare Disease Genetic Testing Market Size & Outlook, 2028

Revenue, 2020 (US$M)

$30.6

Forecast, 2028 (US$M)

$51.5

CAGR, 2021 - 2028

6.7%

Report Coverage

France

France rare disease genetic testing market, 2016-2028 (US$M)

Related Markets

Global Rare Disease Genetic Testing Industry Outlook

North America Rare Disease Genetic Testing Market Outlook

U.S. Rare Disease Genetic Testing Market Outlook

Canada Rare Disease Genetic Testing Market Outlook

Europe Rare Disease Genetic Testing Market Outlook

Germany Rare Disease Genetic Testing Market Outlook

Italy Rare Disease Genetic Testing Market Outlook

Spain Rare Disease Genetic Testing Market Outlook

Netherlands Rare Disease Genetic Testing Market Outlook

UK Rare Disease Genetic Testing Market Outlook

Asia Pacific Rare Disease Genetic Testing Market Outlook

Japan Rare Disease Genetic Testing Market Outlook

China Rare Disease Genetic Testing Market Outlook

India Rare Disease Genetic Testing Market Outlook

Australia Rare Disease Genetic Testing Market Outlook

South Korea Rare Disease Genetic Testing Market Outlook

Singapore Rare Disease Genetic Testing Market Outlook

Latin America Rare Disease Genetic Testing Market Outlook

Brazil Rare Disease Genetic Testing Market Outlook

MEA Rare Disease Genetic Testing Market Outlook

South Africa Rare Disease Genetic Testing Market Outlook

France rare disease genetic testing market highlights

The France rare disease genetic testing market generated a revenue of USD 30.6 million in 2020 and is expected to reach USD 51.5 million by 2028.
The France market is expected to grow at a CAGR of 6.7% from 2021 to 2028.
In terms of segment, immunological disorders was the largest revenue generating disease type in 2020.
Cardiovascular Disorders is the most lucrative disease type segment registering the fastest growth during the forecast period.

Rare disease genetic testing market data book summary

Market revenue in 2020	USD 30.6 million
Market revenue in 2028	USD 51.5 million
Growth rate	6.7% (CAGR from 2020 to 2028)
Largest segment	Immunological disorders
Fastest growing segment	Cardiovascular Disorders
Historical data	2016 - 2019
Base year	2020
Forecast period	2021 - 2028
Quantitative units	Revenue in USD million
Market segmentation	Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disease
Key market players worldwide	Quest Diagnostics Inc, Centogene NV Ordinary Shares, Invitae Corp, Eurofins Scientific SE, PerkinElmer, Macrogenics Inc, Fulgent Genetics Inc, Myriad Genetics Inc, Labcorp Holdings Inc, OPKO Health Inc, 3billion, ARUP Laboratories, Strand Life Sciences, Ambry Genetics, REALM IDx, Inc., Baylor Genetics, Health Network Laboratories, PreventionGenetics, Biora Therapeutics, CooperSurgical, Artemis DNA

Other key industry trends

In terms of revenue, France accounted for 3.9% of the global rare disease genetic testing market in 2020.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
In Europe, Germany rare disease genetic testing market is projected to lead the regional market in terms of revenue in 2028.
UK is the fastest growing regional market in Europe and is projected to reach USD 49.6 million by 2028.

Key Regions: U.S. , UK , Japan , Brazil , Canada

No credit card required*

Horizon in a snapshot

30K+ Global Market Reports
120K+ Country Reports
1.2M+ Market Statistics
200K+ Company Profiles
Industry insights and more

Rare Disease Genetic Testing Market Scope

Rare disease genetic testing market segmentation & scope

Disease Type

Neurological Disorders

Immunological Disorders

Hematology Diseases

Endocrine & Metabolism Diseases

Cancer

Musculoskeletal Disorders

Cardiovascular Disorders

Dermatology Disease

Others

Technology

Next Generation Sequencing

Whole Exome Sequencing

Whole Genome Sequencing

FISH

Specialty

Molecular Genetic Tests

Chromosomal Genetic Tests

Biochemical Genetic Tests

End Use

Research Laboratories & CROs

Hospitals & Clinics

Diagnostic Laboratories

Regions

Europe

Countries

U.S.

Canada

Germany

France

Italy

Spain

Netherlands

Japan

China

India

Brazil

Rare Disease Genetic Testing Market Companies

Name	Profile	# Employees	HQ	Website

France rare disease genetic testing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease genetic testing market will help companies and investors design strategic landscapes.

Immunological disorders was the largest segment with a revenue share of 13.4% in 2020. Horizon Databook has segmented the France rare disease genetic testing market based on neurological disorders, immunological disorders, hematology diseases, endocrine & metabolism diseases, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology disease covering the revenue growth of each sub-segment from 2016 to 2028.

Introduction of French National Plan For Rare Diseases 2018-2022 to advance France position in rare disease management across Europe is expected to boost the adoption if diagnostic services in the country. In addition, strategic alliances between domestic companies as well as global companies to develop diagnostic solutions for rare diseases is expected to boost revenue in the county.

For instance, in February 2018, SeqOne, a French life sciences company, collaborated with Gene42, Inc., a Toronto-based company, to enhance rare disease diagnosis using NGS technology and AI-driven genomic analysis. The market is also expected to be benefitted by conference conducted in the country to address the key concerns in rare disease clinical research and diagnosis.

Reasons to subscribe to France rare disease genetic testing market databook:

Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of France rare disease genetic testing market databook

Our clientele includes a mix of rare disease genetic testing market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the France rare disease genetic testing market , including forecasts for subscribers. This country databook contains high-level insights into France rare disease genetic testing market from 2016 to 2028, including revenue numbers, major trends, and company profiles.